Modest reduction seen in DAS28-CPR at 3 months for those receiving TOF vs ADA, but no difference seen at 9 months.
Your search for tofacitinib returned 14 results
Methods to prevent and treat COVID-19 in cancer patients have had to evolve alongside the SARS-CoV-2 virus.
Researchers examined risk for herpes zoster infection with biologics and small molecules for IBD.
Results of the ORAL Surveillance study showed a higher risk for major adverse CV events and venous thromboembolism with tofacitinib vs TNFis.
The data were compared with the 2018 ACG and 2020 AGA guidelines for UC and the 2019 ACG and 2021 AGA guidelines for CD.
By identifying existing medications that may be repurposed for dementia, clinicians may be able to provide faster treatment for those in need.
Researchers compared the effectiveness of tofacitinib and vedolizumab among patients with UC who had experienced anti-TNF failure.
No reduction in ADRD risk seen for treatment with tofacitinib, tocilizumab, TNF inhibitors versus abatacept
Incidences of major adverse cardiovascular events, cancers higher with tofacitinib versus TNF inhibitor; criteria for noninferiority not met
JAK inhibitor baricitinib strongly recommended for the treatment of severe or critical COVID-19